These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 8666572)

  • 61. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Bruno A; Micò U; Pandolfo G; Mallamace D; Abenavoli E; Di Nardo F; D'Arrigo C; Spina E; Zoccali RA; Muscatello MR
    J Psychopharmacol; 2012 Nov; 26(11):1456-62. PubMed ID: 22351381
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.
    Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M
    CNS Drugs; 2009; 23(3):241-52. PubMed ID: 19320532
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder?
    Mancini C; Van Ameringen M; Farvolden P
    J Affect Disord; 2002 Feb; 68(1):59-65. PubMed ID: 11869783
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
    Brakoulias V; Stockings E
    Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
    Jacobsen FM
    J Clin Psychiatry; 1995 Sep; 56(9):423-9. PubMed ID: 7545159
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: a case-series.
    Thomsen PH
    Ann Clin Psychiatry; 2004; 16(4):201-7. PubMed ID: 15702568
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
    Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
    Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Longitudinal course of pharmacotherapy in obsessive-compulsive disorder.
    Grant JE; Mancebo MC; Weinhandl E; Odlaug BL; Eisen JL; Rasmussen SA
    Int Clin Psychopharmacol; 2013 Jul; 28(4):200-5. PubMed ID: 23587985
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
    Pallanti S; Quercioli L; Bruscoli M
    J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(4):677-82. PubMed ID: 8993091
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
    Hoehn-Saric R; Ninan P; Black DW; Stahl S; Greist JH; Lydiard B; McElroy S; Zajecka J; Chapman D; Clary C; Harrison W
    Arch Gen Psychiatry; 2000 Jan; 57(1):76-82. PubMed ID: 10632236
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.
    Atmaca M; Kuloglu M; Tezcan E; Gecici O
    Int Clin Psychopharmacol; 2002 May; 17(3):115-9. PubMed ID: 11981352
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Bullock KD; Franz B; Gamel N; Elliott M
    J Clin Psychiatry; 2005 Mar; 66(3):353-9. PubMed ID: 15766302
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
    Ramasubbu R
    Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
    [No Abstract]   [Full Text] [Related]  

  • 79. Issues in the pharmacological treatment of obsessive-compulsive disorder.
    Math SB; Janardhan Reddy YC
    Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?
    Carey PD; Lochner C; Kidd M; Van Ameringen M; Stein DJ; Denys D
    Int Clin Psychopharmacol; 2012 Nov; 27(6):321-5. PubMed ID: 22859064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.